UBS raised its price target on Buy-rated Jazz Pharmaceuticals (NASDAQ: JAZZ) from $64 to $67 following Q4 beat and outlook.
This article: 149 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE